Glenmark Pharma discovers new anti-cancer molecule

Glenmark Pharmaceuticals has announced the discovery of a new molecule for oncology treatment and would file an application for phase-I trials in the fourth quarter of FY12. Developed at Glenmark's Switzerland-based research centre, the GBR 401 molecule is an anti-CD19 monoclonal antibody primarily targeted for treating lymphoma and leukemia of B-cell origin. In addition, the molecule also has potential to treat disorders like rheumatoid arthritis. The molecule is in the same segment of anti-cancer biotech product rituximab, which had annual global sales of $6 billion.crackcrack